Research programme: mucin 1 inhibitors - Minerva Biotechnology

Drug Profile

Research programme: mucin 1 inhibitors - Minerva Biotechnology

Latest Information Update: 23 Oct 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Minerva Biotechnology
  • Class Antibodies; Small molecules
  • Mechanism of Action Mucin 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer

Most Recent Events

  • 10 Oct 2013 Preclinical development is ongoing in USA
  • 12 May 2009 Early research in Breast cancer in USA (unspecified route)
  • 12 May 2009 Pharmacodynamics data from a preclinical trial in cancer were released by Minerva Biotechnology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top